Breast-cancer drug letrozole picks up where tamoxifen leaves off. But we don't know who stands to benefit the most from this follow-up approach.
Runowicz, Carolyn D.
; 9(12): 4-5, 2003 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-14679962
Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial.
Overcoming recurrence risk: extended adjuvant endocrine therapy.
Prescribing extended adjuvant letrozole.
Aromatase inhibitors in breast cancer prevention.
When to start an aromatase inhibitor: now or later?
Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy: a 5-year follow-up.
Patients' knowledge and experience of adjuvant endocrine therapy for early breast cancer: a European study.
Letrozole in breast cancer.
Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen and aromatase inhibitors.
Recent advances in the use of aromatase inhibitors for women with postmenopausal breast cancer.